DEVELOPMENT AND VALIDATION METHOD OF CYCLOPHOSPHAMIDE AND 4-HYDROXYCYCLOPHOSPHAMIDE WITH 4-HYDROXYCYCLOPHOSPHAMIDE-D4 AS INTERNAL STANDARD IN DRIED BLOOD SPOTS USING UPLC-MS/MS

Authors

  • YESI IHDINA FITYATAL HASANAH Bioavailability and Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, 16424 Depok, Indonesia
  • YAHDIANA HARAHAP Bioavailability and Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, 16424 Depok, Indonesia, Indonesia Defense University, Bogor, 16810, West Java, Indonesia
  • HERMAN SURYADI Bioavailability and Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, UI Depok Campus, 16424 Depok, Indonesia

DOI:

https://doi.org/10.22159/ijap.2021v13i2.39590

Keywords:

4-hydroxycyclophosphamide (4-OHCP), Cyclophosphamide (CP), Dried blood spots (DBS), SIL 4-hydroxycyclophosphamide-d4

Abstract

Objective: Cyclophosphamide (CP) is anticancer of the alkylating agent (nitrogen mustard) and a prodrug which will be metabolized into an active metabolite form, 4-hydroxycyclophosphamide (4-OHCP). Therefore, the effectiveness of therapy with CP is determined by its metabolites concentration. The purpose of this study was to obtain a validated analytical method of CP and 4-OHCP simultaneously and sensitively in dried blood spots with SIL (Stable Isotope Labeled) 4-OHCP-d4 as the internal standard using liquid chromatography-tandem mass spectrometry, so optimization and full validation are conducted in this research.

Methods: A simpler analytical method was developed and validated to quantify CP and 4-OHCP in DBS samples using an Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS). A linear regression was used as the statistical analysis method. Sample preparation was performed by protein precipitation using methanol. The separation was performed on UPLC H-Class BEH C18 column using formic acid 0.01%-acetonitrile as the mobile phase in gradient mode at 0.2 ml/minute. The mass detection was performed on Waters Xevo TQD using ESI+for CP, 4-OHCP-SCZ, and IS 4-OHCP-d4-SCZ with m/z value: 261.03>140.16; 334.10>221.04; and 338.10>225.06.

Results: This method was linear within the range of 10–40,000 ng/ml for CP and 5–4,000 ng/ml for 4-OHCP. Lower Limit of Quantification (LLOQ) concentration of CP was 10 ng/ml and 4-OHCP was 5 ng/ml.

Conclusion: This method has successfully fulfilled the validation requirement referring to the 2011 EMA and 2018 FDA guidelines.

Downloads

Download data is not yet available.

References

International Agency for Research on Cancer (IARC). IARC monographs-100A: Cyclophosphamide. IARC-WHO, Paris; 2012.

Ekhart C, VD Doodeman, S Rodenhuis, PH Smits, JH Beijnen, ADR Huitema. Influence of polymorphisms of drug-metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxy-cyclophosphamide. Pharmacogenet Genom 2008;18:515-23.

Helsby NA, M Yong, M Van Kan, JR de Zoysa, KE Burns. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. Br J Clin Pharmacol 2019;85:1–10.

Ekhart C, A Gebretensae, H Rosing, S Rodenhuis, JH Beijnen, ADR Huitema. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC–SM/SM). J Chromatogr B Biomed Appl 2007;854:345–9.

Harahap Y, C Samuel, R Andalusia, NF Syafhan. Analysis of 4-hydroxycyclophosphamide in cancer patients plasma for therapeutic drug monitoring of cyclophosphamide. Int J Pharm Pharm Sci 2016;8:194-200.

Harahap Y, N Gustiyanti, AEM Sunanto, Harmita, DJ Purwanto. Method development on analysis cyclophosphamide and 4-hydroxycyclophophamide in dried blood spot and its application in breast cancer patients. Int J Appl Pharm 2020;12:119-25.

Shu W, Wang X, Yang X, Liang L, Li J, Chen Z, et al. Simultaneous determination of cyclophosphamide and 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry–application to Chinese systemic lupus erythematosus patients. Clin Chem Lab Med 2011;49:2029–37.

FA de Castro, S Scatena Gdos, OP Rocha, MP Marques, QB Cass, BP Simoes, et al. Enantioselective analysis of 4-hydroxycyclophosphamide in human plasma with application to a clinical pharmacokinetic study. J Chromatogr B: Anal Technol Biomed Life Sci 2015;1011:53–61.

Hall OMH, Peer CJ, Fitzhugh CD, Figg WD. A sensitive and rapid ultra-high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxy-cyclophosphamide metabolite in human plasma. J Chromatography B 2018;1086:56–62.

Hong PS, Chan KK. Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma. J Chromatogr 1989;495:131–8.

Anderson LW, SM Ludeman, OM Colvin, LB Grochow, JM Strong. Quantitationof4-hydroxycyclophosphamide/aldophosphamide in whole blood. J Chromatogr Biomed Appl 1995;667:247–57.

Baumann F, C Lorenz, U Jaehde, R Preiss. Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;729:297–305.

Food and Drug Administration (FDA). Guidance for industry bioanalytical method validation. FDA, Rockville; 2018.

European Medicines Agency (EMEA). Guideline on bioanalytical method validation. EMEA, London; 2011.

Waters. Controlling contamination in LC/MS systems. Waters Coprporation; 2016.

Lee Chuin Chen. High-temperature liquid chromatography and the hyphenation with mass spectrometry using high-pressure electrospray ionization. Mass Spectrom 2019;8:S0079.

Dong MW. HPLC and UHPLC for practicing scientists. Wiley, USA; 2019.

Bose, Anirban Deep. HPLC calibration process parameters in terms of the system suitability test. Austin Chromatogr 2014;1:1-4.

Published

07-03-2021

How to Cite

HASANAH, Y. I. F., HARAHAP, Y., & SURYADI, H. (2021). DEVELOPMENT AND VALIDATION METHOD OF CYCLOPHOSPHAMIDE AND 4-HYDROXYCYCLOPHOSPHAMIDE WITH 4-HYDROXYCYCLOPHOSPHAMIDE-D4 AS INTERNAL STANDARD IN DRIED BLOOD SPOTS USING UPLC-MS/MS. International Journal of Applied Pharmaceutics, 13(2), 148–152. https://doi.org/10.22159/ijap.2021v13i2.39590

Issue

Section

Original Article(s)

Most read articles by the same author(s)

<< < 1 2 3 4 > >>